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An even more recent trend in risk modeling has been the addition of various biomarkers to supplement clinical risk predictors. Because of their exquisite sensitivity, these biomarkers may provide incremental predictive value beyond that available from clinical data, thus facilitating the detection of subclinical phenomena or providing objective confirmation of clinical impressions. Two such biomarkers-Troponin T (TNT) and Beta-Type Natriuretic Peptide (BNP)--are the subject of a study by Lurati-Buse and colleagues in the current issue of TNT is a sensitive marker of myocardial cell injury, often used in the evaluation and risk stratification of patients with acute coronary syndromes. TNT has also been studied in patients undergoing CABG, including previous investigations by the authors of the current study, and elevated levels are associated with less favorable short and longer term outcomes [3] [4] [5] [6] . In CABG patients, TNT levels may be elevated preoperatively due to acute coronary syndromes of varying severity and acuity. Even when preoperative levels are normal, as in many elective surgical patients, postoperative elevations of this sensitive biomarker occur due to cardiac incisions or manipulation, defibrillation, reperfusion, or myocardial injury from inadequate protection.
Substantially elevated postoperative levels in some patients may alert providers to the need for enhanced follow-up in an attempt to mitigate short and long-term consequences, and they may also suggest the need to re-evaluate surgical strategies (e.g., myocardial protection).
BNP is released in response to ventricular volume or pressure overload or ischemia 7 .
Clinically, BNP elevations are most commonly associated with ventricular dysfunction or heart failure and portend a worse prognosis. In CABG, Fox et al 7-10 showed that increased preoperative and peak postoperative BNP levels (especially the former) were independently tratification of patients with acute coronary syndromes. TNT has also been studi di ied ed d i in n pa pa pati ti tien en ents ts undergoing CABG, including previous investigations by the authors of the current study, and el lev ev vat at ated ed ed l l lev ev evel el e s ar ar re e e a associated with less favorable le e sh h hort and longe er r r term m m o o out u comes [3] [4] [5] [6] . In CABG pati i ien e ts, TNT T le leve ve vels s m m may ay y b b be e el el elev eva at ate ed ed p p pr re eope er era a ative el ly y d due ue ue t to o a ac cut ute e c co coro ron na nary ry s s syn y yndr drom om omes es of f f va vary ry ryi ing e eve ve veri ri rity ty ty a and nd nd a acu cui i ity y. y. E Eve ven n wh wh hen en e p p pre re reo op ope er erat at ativ iv ive e e le le eve ve v l ls a are e e n n nor or orma ma mal, l, l a a as in in in m m man n ny y e el elec ec cti tiv ve ve s sur r rgi ica cal l patients, post stop op oper er e at at ativ iv i e e e el e e ev v vat at atio i i ns ns ns o of f f th this is is s s sen en ensi si siti ti ive ve e b b bio io ioma ma ark rk rker er er o o occ cc ccur ur ur d d due ue ue t t to o o c c car ar a di di d ac ac ac i i inc nc ncis i ions or by guest on July 26, 2017 http://circ.ahajournals.org/ Downloaded from associated with early cardiac dysfunction, longer length of stay, and decreased long-term survival and physical functioning. As with TNT, it is possible that we may be able to provide more than just enhanced follow-up of patients with elevated perioperative BNP levels. For example, at least for elective procedures, might there be an opportunity to use preoperative BNP as a marker of increased risk and to modify perioperative management accordingly. In ambulatory heart failure, for example, numerous studies have shown that BNP-guided medical management designed to blunt BNP increases may improve outcomes and overall functioning 7, [11] [12] [13] [14] .
In the current study, Lurati-Buse and colleagues 2 report that addition of these two congestive h hea ea art rt rt f f fai ai ailu lu l re re r reui ui uiri r r ng ng ng ho ho osp spit it ital al aliz iz izat at atio io ion] n] n] w w wit it i hi hin n n 1 1 1 ye ye yea a ar) r) r); ; ; an n nd d d 6. 6. 6.6% 6% 6% o of f f pa pa pati ti tien en ents ts t died. elevated biomarkers whose events occurred at a median of 87 days (p <0.001), suggesting to the authors an opportunity for intervention such as "more stringent in-hospital monitoring in stepdown units or systematic telemetry monitoring on the regular ward, dedicated post-cardiac surgery outpatients clinics, or virtual wards" 2 .
Although the current study adds some new information, such as adjustment for complications, it also presents methodological concerns and opportunities for future investigation. For example, the authors regard it as a strength of their study that they included all consecutive cardiac surgery patients, ranging from isolated CABG to CABG plus valve and multiple valve procedures. Heterogeneous study cohorts such as this are often chosen in order to increase sample size and statistical power. The STS National Database has generally taken a different tact in developing and applying risk models, believing it is preferable to create more homogeneous patient cohorts (e.g., isolated CABG, isolated AVR) [15] [16] [17] [18] . This reduces extraneous sources of variation--noise--resulting from the aggregation of highly disparate procedures, and instead allows the analyses to focus on the source of variation that is of real interest, in this case the association of biomarkers with clinical outcomes. We might expect, for example, that the relative elevations of TNT and BNP would be quite different among the diverse group of procedures included in the current study 2 . In CABG patients with acute coronary syndromes, TNT elevation might predominate, whereas in patients with chronic aortic regurgitation and heart failure, BNP elevations might be more prominent. Using homogeneous procedure cohorts would allow a more critical examination of these two biomarkers.
Use of the original Euroscore as the benchmark risk model in this study is also somewhat problematic 19 . If the goal is to assess the incremental benefit of biomarkers to the predictive accuracy of existing clinical risk models, then it is only fair that the most contemporary and best ncrease sample size and statistical power. The STS National Database has gene era rall ll ly y y ta ta ake ke ken n n a a a different tact in developing and applying risk models, believing it is preferable to create more Subsequent studies including these additional complications would be useful to more convincingly validate the additive value of biomarkers.
The timing of biomarker collection in the current investigation 2 --6 AM on postoperative days 1 and 2-may not be optimal, and this also provides fertile opportunities for additional study. Previous reports by Fox and colleagues 7, 8, 10 demonstrated that postoperative BNP increased significantly for the first 3 days postoperatively, then plateaus or decline by days 4 and 5, leading them to use peak rather than early postoperative BNP levels for their analyses. Collection of specimens only on the first two postoperative mornings would therefore potentially miss the peak values.
In addition to obtaining additional postoperative biomarker samples beyond day 2, it would also be interesting to repeat these studies with adjustment for preoperative TNT or BNP, or to design analyses that compare the added predictive value of preoperative and postoperative determinations. Early postoperative biomarker elevations may reflect residually elevated preoperative levels due to myocardial injury or heart failure; elevations due to intraoperative management or events; or a combination of both. Studies by Fox and colleagues 8 suggest that preoperative BNP may be a better predictor of length of stay and longer term mortality after CABG than peak postoperative BNP, although postoperative BNP may be useful if preoperative values are not available. From a pathophysiologic perspective, it would certainly be more satisfying to know the temporal pattern of biomarker elevations, which may help to better understand both causality and potential mitigation. for people who do not develop events. We call this sum the NRI." 20 The theoretical range of each of these two components of the overall NRI is -1 (or -100%) to + 1 (or +100%), and the theoretical range of the overall NRI is thus -2 to +2 21 .
Despite its growing popularity, NRI has not always been applied or interpreted correctly, and some even question its theoretical foundation [21] [22] [23] . The current study illustrates one important feature of this method--the importance of always considering the two components of the overall NRI (NRI for events and non-events) separately. The overall NRI associated with addition of TNT and BNP to the EuroSCORE was 0.276. Decomposing the two components of the overall NRI, as described above, there was reasonably strong performance of the new biomarker in detecting increased risk in patients who actually sustained an event (NRI events 0.696 ) but very poor performance in correctly reclassifying non-event patients (NRI non-events -0.420). In other words, among 100 patients not suffering MACE, a net of 42 would be misclassified "up" by the biomarker-augmented model, which is not reassuring performance.
In conclusion, the study of Lurati Buse and colleagues 2 is an interesting addition to the growing literature on the utility of biomarkers in CABG risk prediction, and the authors are to be congratulated for their pioneering work in this area. Subsequent studies should address the methodological issues discussed in this review, which would add even more to our understanding of this complex issue. Finally, although identification of patients at higher risk for short and long why these molecules are released in cardiac surgery patients (the contributions of a patient's presenting disease state versus the effects of surgery and anesthesia). Ultimately, the goal is to mitigate, when possible, the factors that lead to biomarker elevations, thereby potentially improving outcomes.
